NN Balanced Scorecard
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Go Beyond the Preview-Access the Full Balanced Scorecard
This NN Balanced Scorecard Analysis gives a clear, company-specific view of NN's strategic priorities across financial, customer, internal process, and learning and growth dimensions. The page already shows a real preview of the actual report content, so you can review what's included before buying. Purchase the full version to get the complete ready-to-use analysis.
Benefits
Accelerated Deleveraging Alignment
NN's Balanced Scorecard keeps net leverage tightly anchored to the 3.0x-3.5x target range in fiscal 2025, so operating gains feed straight into debt paydown. When factory output, yield, and cash conversion improve, less cash gets trapped in working capital and more goes to deleveraging. That link makes every plant fix a balance-sheet move, not just a margin win.
Segment-Specific Strategic Focus
Segment-specific KPIs let NN manage different cycles in medical and aerospace without forcing one scorecard on both. That matters because medical can support long R&D paybacks, while power solutions need tighter volume and efficiency control.
In 2025, keeping the medical segment near a 15% margin gives room to fund innovation, while the other units can push output and cash conversion.
Supply Chain Resiliency Scores
Supply Chain Resiliency Scores help NN monitor vendor performance and material availability in real time across its global precision component network. In fiscal 2025, that matters because NN runs 40-plus manufacturing facilities, so even small disruptions can show up fast in service levels and COGS variance. The scorecard also helps flag commodity price swings early, so managers can act before margin pressure spreads.
High-Value Portfolio Transition
The scorecard shows whether NN is shifting out of low-margin legacy components and into higher-return medical and defense work. Tracking New Product Revenue in 2025 helps leadership see if capex is funding the mix that should lift margins, not just volume. That makes the portfolio move measurable, so management can back winners and cut weak lines faster.
Operational Excellence Visibility
NN ties lean manufacturing metrics to shop-floor control, so scrap rates and machine uptime are visible in one scorecard. That matters in metal and plastic production, where small defects or downtime can quickly hit margin. The link is direct: better operational discipline supports the 12 percent adjusted EBITDA margin goal for 2026.
For NN, operational excellence visibility turns daily output data into a financial signal, making it easier to spot waste, protect throughput, and hold plants accountable.
NN's 2025 Scorecard: Cash Discipline, Faster Deleveraging
NN's Balanced Scorecard in fiscal 2025 turns operating gains into cash, helping keep net leverage near the 3.0x-3.5x target. With 40-plus plants and a 15% medical margin target, the scorecard links uptime, yield, and working capital to faster deleveraging. It also makes supply risk and mix shift visible, so higher-return medical and defense work can lift returns.
| Fiscal 2025 signal | Benefit |
|---|---|
| 3.0x-3.5x net leverage | Cash discipline |
| 40+ plants | Faster issue spotting |
| 15% medical margin | Funds innovation |
What is included in the product
Detailed Word Document
Editable Excel File
Drawbacks
Implementation Reporting Fatigue
With more than 40 global sites feeding the Balanced Scorecard, middle managers can spend too much time collecting, cleaning, and reconciling data instead of acting on it. That load often turns reporting into box-ticking, where plants focus on meeting templates and deadlines rather than deeper operational insight. In a network this broad, even a small reporting delay across 40+ sites can blur root-cause analysis and weaken strategic follow-through.
Financial Goal Overshadowing
A 4.0x leverage target can pull attention toward debt cuts and near-term margin defense, even when 2025 spending should protect R&D. That tradeoff matters because medical component demand is tied to 2027-2028 product cycles, where missed development work can hit future orders. In practice, short-term financial discipline can look safer now but weaken NN Balanced Scorecard innovation output later.
Cross-Segment Metric Friction
Cross-segment metric friction shows up when NN applies one Standard Work scorecard to aerospace components and power grid parts, even though their qualification and delivery cycles are very different. A uniform metric can punish a team serving long-cycle aerospace orders while overstating the ease of a faster grid-part flow. In 2025, that rigidity can push local managers to optimize the scorecard, not the business.
Data Fragmentation Risks
Fragmented ERP systems across legacy acquisitions can make NN's scrap-rate and labor-productivity reporting inconsistent, so leaders may compare like with unlike. When data arrives four weeks late, plant issues can move from minor variance to costly waste before action is taken.
That lag weakens the Balanced Scorecard's internal-process view because decisions reflect stale shop-floor conditions, not current output. In practice, even a 1-point swing in scrap or productivity can distort margin and capex calls if the underlying sites are reporting on different clocks.
Execution Velocity Bottlenecks
Execution velocity bottlenecks show up fast in a balanced scorecard, but they are hard to fix when the financial view keeps cash tight. A new precision molding line can cost $250,000 to over $1 million, so a debt-first capital policy can leave a known constraint unchanged. That means the scorecard flags the delay, but it does not fund the machine, hire, or setup needed to remove it.
NN's Balanced Scorecard Risks Missing the Real Signals in 2025
NN's Balanced Scorecard can get noisy in 2025: 40+ sites create heavy data work, and four-week reporting lags can leave plant issues hidden until margins slip. A 4.0x leverage target also pushes cash discipline over R&D, which can hurt 2027-2028 order cycles. One scorecard can fit neither aerospace nor grid parts well, so managers may game the metric, not fix the business.
| Drawback | 2025 impact |
|---|---|
| 40+ sites | Slower, noisier reporting |
| 4.0x leverage | Less R&D spend |
| 4-week lag | Stale decisions |
What You See Is What You Get
NN Reference Sources
This preview shows the actual NN Balanced Scorecard Analysis document you'll receive after purchase, with the same structure and content. There are no hidden sections or placeholders-what you see here is the real file. After checkout, you'll unlock the full version ready to review and use.
Frequently Asked Questions
NN utilizes the financial perspective to link every operating unit's cash flow to the overarching 3.5x net leverage target. By March 2026, the company has integrated 'free cash flow conversion' as a primary KPI for facility managers, directly impacting 100 percent of their performance-based incentives to ensure total organizational alignment with the de-risking strategy.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.